In what the FDA is calling a "mutually agreed upon decision" between CDRH Director Daniel Schultz and FDA Commissioner Margaret Hamburg, Schultz announced his resignation last week, effective at the end of the month. Jeff Shuren, the FDA's associate commissioner for policy and planning, will serve as interim CDRH director, Hamburg says in an internal FDA email last week. A career employee at the FDA, Schultz has led CDRH for the past five years. His tenure has been marked by controversy, internal criticism and congressional investigations.